

**ASX ANNOUNCEMENT**

**5 August 2025**

## **Investor Webinar**

**Melbourne, Australia; 5 August 2025:** [Cynata Therapeutics Limited](#) (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, reminds shareholders that CEO and Managing Director, Dr Kilian Kelly, will host an investor webinar today, Tuesday 5 August 2025 at 11:00am AEST.

Attendees are required to register in advance for the webinar using the following link:  
[https://us02web.zoom.us/webinar/register/WN\\_CeYzDI8lSkWOSzWOvkbCjQ](https://us02web.zoom.us/webinar/register/WN_CeYzDI8lSkWOSzWOvkbCjQ)

Upon registration, attendees will receive details to access the webinar.

A copy of the presentation to be delivered during the webinar is attached to this announcement.

**-ENDS-**

**Authorised for release by Dr Kilian Kelly, CEO & Managing Director**

**CONTACTS:** Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, [kilian.kelly@cynata.com](mailto:kilian.kelly@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [investors@cynata.com](mailto:investors@cynata.com)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods.

Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, [Automic Group](#).



# Investor Webinar: Quarterly Update

5 August 2025



# Important information

## Summary information

This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries (**CYP**, or **Cynata**) which is current as at 4 August 2025. This Presentation should be read in conjunction with CYP's other periodic and continuous disclosure information lodged with the Australian Securities Exchange (**ASX**), which are available at [www.asx.com.au](http://www.asx.com.au).

## Not an offer

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

## Not investment advice

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation by CYP or its advisers to acquire CYP securities. This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. CYP is not licensed to provide financial product advice in respect of CYP securities.

## Investment risk and past performance

An investment in CYP securities is subject to known and unknown risks, some of which are beyond the control of CYP and its directors. CYP does not guarantee any particular rate of return or performance of CYP. Past performance cannot be relied upon as an indicator of (and provides no guidance as to) future CYP performance including future share price performance.

## Financial data

All financial information in this Presentation is in Australian currency (A\$) unless otherwise stated. This Presentation contains historical financial information based on financial information that has been disclosed to the ASX. Any discrepancies between totals and sums of components in tables and figures in this Presentation are due to rounding.

## Forward-looking statements

This Presentation contains certain 'forward-looking statements', which can generally be identified by the use of forward looking words such as 'expect', 'anticipate', 'likely', 'intend', 'should', 'could', 'may', 'predict', 'plan', 'propose', 'will', 'believe', 'forecast', 'estimate', 'target', 'outlook', 'guidance', 'potential' and other similar expressions. The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of CYP, its directors and management, and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not differ materially from these forward looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward looking statements are based on information available to CYP as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), CYP and its directors, officers, employees, advisers, agents and intermediaries undertake no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. You are strongly cautioned not to place undue reliance on forward-looking statements.

## Industry and Market data

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither CYP nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications.

## Disclaimer

To the maximum extent permitted by law, CYP and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (**Related Persons**) exclude and disclaim all liability, including without limitation for negligence, for any expenses, losses, damages or costs arising from this Presentation or reliance on anything contained in or omitted from it. To the maximum extent permitted by law, CYP and its Related Persons make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation and disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice.

# Capital Structure

## Financial information

Share price (4 August 2025)	A\$0.17
Shares on issue	~225m
Market capitalisation	~A\$38m
Cash runway to mid-calendar year 2026	

## Largest shareholders



10.4%



9.3%



3.6%


Top 20 shareholders hold >47% of shares on issue

- **Backed by institutions:** Fidelity, BioScience Managers, and Fujifilm among top holders
- **Funded through milestones:** Cash runway secured to mid-2026 – through landmark clinical readouts
- **Attractive valuation:** Market cap does not reflect advanced clinical pipeline and near-term catalysis
- **Tightly held register:** Top 20 own ~47%, creating scarcity value on good news



# **June 2025 Quarter – Key Highlights**

# Conventional manufacturing



## Challenges:

- Continuously finding new donors is **logistically challenging** and **costly**
- Substantial variability between donors: different donors → **inconsistent product**
- MSCs **change** when culture expanded
- Extensive** MSC culture expansion required → **loss of function** and **potency**

# Cymerus™ platform



One donor, one time

iPSC Master Cell Bank


Proprietary Cymerus™ technology turns iPSCs into MSCs



## The Solution:

- Enormous **scalability**
- New donors **not required**
- Same** starting material for all batches → **consistent product**
- Avoids** extensive MSC culture expansion
- Produces **consistent** MSCs with **improved function** and **potency**

# Clinical pipeline





# CYP-001: Phase 2 clinical trial in aGvHD<sup>1</sup>

- Trial being conducted in Australia, USA, and Europe
- Patient enrolment now >75% complete
- Completion of enrolment anticipated within coming months
- Primary results (after 100 days' follow-up) anticipated **1H 2026**





# CYP-004: Phase 3 clinical trial in osteoarthritis

- Trial being conducted in Australia
- Enrolment and treatment of all 321 patients **complete**
- Final results anticipated **Feb-Apr 2026**
- Following a recent advisory meeting with the TGA<sup>2</sup>, Cynata is optimistic that positive results could support marketing approval of CYP-004 in Australia

1. Trial being conducted by University of Sydney & funded by National Health and Medical Research Council  
2. TGA = (Australian) Therapeutic Goods Administration



# CYP-001: Phase 1 clinical trial in kidney transplantation

- Trial being conducted in the Netherlands<sup>1</sup>
- Enrolment and treatment of patients in Cohort 1 (n=3) now complete
- After patients have been followed for 6 weeks, the DSMB<sup>2</sup> will review data from this Cohort
- Results of this review are anticipated by **Q4 2025**



# Positive preclinical data in ischaemic heart disease

- The study<sup>1</sup> tested a new encapsulation device<sup>2</sup> that delivers MSC-derived factors over time
- In rat models of heart attack, treated animals showed significantly improved cardiac function, reduced scar tissue, and lower levels of heart muscle thickening
- These findings were supported by *in vitro* data using 3D human heart tissue (“cardiac spheroids”), which demonstrated enhanced tissue survival and function

1. Study conducted in collaboration with academic partners, including: University of Melbourne; Baker Heart and Diabetes Institute; La Trobe University; Monash University; University of South Australia; Hearts4heart; St Vincent's Hospital, Melbourne; Westmead Hospital; The Westmead Institute for Medical Research; University of Toronto and The Hospital for Sick Children; University of Arizona; University College London; Duke-NUS Medical School; National University Singapore; National Heart Research Institute Singapore.

2. Device supplied by Procyon Technologies LLC (Tucson, Arizona, USA)



# Outlook




# Momentum Building into a Catalyst-Rich Period

- Pivotal period approaching, with **three** clinical trial readouts anticipated during this financial year
- All targeting large markets with limited treatment options and high unmet need
- Our strategy is to develop multiple candidate products in clinical indications of high unmet need
- Cash runway to mid-calendar year 2026, beyond all three expected upcoming clinical readouts

# Upcoming catalysts\*

Results from **three** further trials expected **this financial year**





**Cynata Therapeutics Ltd**  
Level 3, 100 Cubitt Street  
Cremorne, Victoria 3121, Australia



[info@cynata.com](mailto:info@cynata.com)



[www.cynata.com](http://www.cynata.com)

